This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Video Lectures

PSMA Targeted Therapy

The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor
July 19, 2022
Details
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
June 16, 2022
Details
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
April 3, 2022
Details
Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor
March 28, 2022
Details
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
March 10, 2022
Details
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
December 16, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
October 3, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
July 20, 2021
Details
Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor
June 23, 2021
Details
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor
June 7, 2021
Details
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
June 4, 2021
Details
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
March 22, 2021
Details
Targeted Radionuclide Therapy of Prostate Cancer - Wolfgang Weber
June 21, 2020
Details
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis
May 29, 2020
Details
TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman
May 8, 2020
Details
Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa
March 30, 2020
Details
The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman
March 30, 2020
Details
Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni
January 8, 2020
Details
Outcomes of Patients From PSMA Targeted Radionuclide Trials - Panagiotis Vlachostergios
August 8, 2020
Details
High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman
December 27, 2019
Details
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
November 18, 2019
Details
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
October 31, 2019
Details
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
October 14, 2019
Details
PSMA Targeted Therapies Presentation - Michael Hofman
September 18, 2019
Details
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
February 25, 2019
Details
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais
February 4, 2019
Details
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free